Current methods for monitoring HIV-infected patients on antiretroviral therapy are expensive and technologically complex, making it difficult for use in resource-limited countries around the world. To advance the field, NIAID has resources available to assist investigators who wish to evaluate new technologies that are cost-effective, easy to use, and can monitor HIV disease, identify acute/early infection, and differentiate vaccine-induced immunity from HIV infection. Alternative test technologies may also be of interest, including HIV drug resistance testing, diagnosis of co-infecting pathogens, and Pharmacokinetics (PK) and Pharmacodynamics (PD) testing.
Through a specified contractor, NIAID can provide an independent evaluation of a product at no cost to the investigator. These services are offered to fill specific gaps in an investigator’s assay development plan to help advance the product towards large-scale clinical use and/or Food and Drug Administration approval. The evaluation may include testing in laboratories at domestic and international NIAID-sponsored clinical trial sites. The contractor will have ongoing communication with the investigator. When the evaluation is completed, the contractor will provide a detailed report to NIAID and the investigator.
Last Updated April 12, 2010
Last Reviewed April 12, 2010